{"id":"efi-act-385781a","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Nasal congestion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug selectively antagonizes endothelin receptors, which are overexpressed in pulmonary hypertension. By blocking endothelin-1, a potent vasoconstrictor, the compound reduces pulmonary vascular remodeling and improves right ventricular function. This mechanism is designed to provide therapeutic benefit in pulmonary arterial hypertension with potentially improved selectivity or tolerability compared to non-selective endothelin antagonists.","oneSentence":"EFI/ACT-385781A is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:42.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT01470144","phase":"PHASE3","title":"Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":41},{"nctId":"NCT01431716","phase":"PHASE3","title":"Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-03","conditions":"Pulmonary Arterial Hypertension","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACT-385781A","Epoprostenol for injection (EFI)"],"phase":"phase_3","status":"active","brandName":"EFI/ACT-385781A","genericName":"EFI/ACT-385781A","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EFI/ACT-385781A is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}